SG11201908054XA - Methods and compositions for treating cancers using antisense - Google Patents

Methods and compositions for treating cancers using antisense

Info

Publication number
SG11201908054XA
SG11201908054XA SG11201908054XA SG11201908054XA SG11201908054XA SG 11201908054X A SG11201908054X A SG 11201908054XA SG 11201908054X A SG11201908054X A SG 11201908054XA SG 11201908054X A SG11201908054X A SG 11201908054XA SG 11201908054X A SG11201908054X A SG 11201908054XA
Authority
SG
Singapore
Prior art keywords
international
compositions
methods
antisense
philadelphia
Prior art date
Application number
SG11201908054XA
Inventor
David Andrews
Douglas Hooper
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of SG11201908054XA publication Critical patent/SG11201908054XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

Title: METHODS AND COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE (57) : The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF- IR). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma. PMMA hemirings FIG. 1A W O 20 18/ 1655 28 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT 0111111010 0111 °nolo VIII ono iflo oimIE (10) International Publication Number WO 2018/165528 Al (51) International Patent Classification: C12N 5/02 (2006.01) Cl 2N 15/113 (2010.01) C12N 5/10 (2006.01) Cl 2P 19/34 (2006.01) C12N 15/09 (2006.01) CO7H 21/04 (2006.01) C12N 15/11 (2006.01) C12Q 1/68 (2018.01) C12N 15/52 (2006.01) (21) International Application Number: PCT/US2018/021706 (22) International Filing Date: 09 March 2018 (09.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/469,003 09 March 2017 (09.03.2017) US 62/629,972 13 February 2018 (13.02.2018) US (71) Applicant: THOMAS JEFFERSON UNIVERSITY [US/US]; 901 Walnut Street, Innovation Pillar, 11th Floor, Philadelphia, PA 19107 (US). (72) Inventors: ANDREWS, David, W.; 8882 Norwood Av- enue, Philadelphia, PA 19118 (US). HOOPER, Douglas, C.; 2 Oregon Trail, Medford, NJ 08055 (US). (74) Agent: VOS STRACHE, Kyle; Cozen O'Connor, 1650 Market Street, One Liberty Place, Suite 2800, Philadelphia, PA 19103 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] WO 2018/165528 Al MIDEDIM01101 DIDIREIE311111111111111111111111101111111111111111111 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201908054XA 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense SG11201908054XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469003P 2017-03-09 2017-03-09
US201862629972P 2018-02-13 2018-02-13
PCT/US2018/021706 WO2018165528A1 (en) 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense

Publications (1)

Publication Number Publication Date
SG11201908054XA true SG11201908054XA (en) 2019-09-27

Family

ID=62838976

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908054XA SG11201908054XA (en) 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense
SG10202109912X SG10202109912XA (en) 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202109912X SG10202109912XA (en) 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense

Country Status (13)

Country Link
US (5) US10357509B2 (en)
EP (1) EP3592841B1 (en)
JP (2) JP2020510021A (en)
KR (1) KR20190140440A (en)
CN (1) CN110832068A (en)
AU (1) AU2018230458A1 (en)
BR (1) BR112019018555A2 (en)
CA (1) CA3054662A1 (en)
MX (1) MX2019010725A (en)
NZ (1) NZ756820A (en)
RU (1) RU2766457C2 (en)
SG (2) SG11201908054XA (en)
WO (1) WO2018165528A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108260357A (en) 2015-04-10 2018-07-06 托马斯杰弗逊大学 For reducing immunological regulation M2 monocytes treating cancer by selectivity and enhancing the method and composition of therapeutic immunity
RU2766457C2 (en) 2017-03-09 2022-03-15 Томас Джефферсон Юнивёрсити Methods and compositions for treating cancer using antisense
JP7406213B2 (en) * 2018-01-24 2023-12-27 トーマス・ジェファーソン・ユニバーシティ Biodiffusion chamber and its manufacturing method
WO2020069087A1 (en) * 2018-09-26 2020-04-02 Thomas Jefferson University Neoantigen compositions; and methods of preparation and use thereof
US20220000916A1 (en) * 2018-11-02 2022-01-06 Thomas Jefferson University Methods and compositions for treating breast cancer using antisense
MX2021005169A (en) * 2018-11-02 2021-08-05 Univ Jefferson Methods and compositions for treating hepatocellular carcinoma using antisense.
JP2022527473A (en) * 2019-03-28 2022-06-02 トーマス・ジェファーソン・ユニバーシティ Methods for treating cancer with antisense

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
EP0750516A4 (en) 1993-03-26 1998-07-01 Univ Jefferson Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides
US5714170A (en) 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
US6541036B1 (en) * 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
EP1105150A1 (en) * 1998-08-13 2001-06-13 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor
US6144553A (en) 1998-09-09 2000-11-07 Sun Microsystems, Inc. Refrigeration cooled disk storage assembly
US7037335B2 (en) 2002-11-19 2006-05-02 Eagle Vision, Inc. Bulbous scleral implants for the treatment of eye disorders such as presbyopia and glaucoma
NZ541637A (en) 2003-02-11 2008-07-31 Antisense Therapeutics Pty Ltd Modulation of insulin like growth factor I receptor
US7846906B2 (en) 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CA2447400A1 (en) 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
JP6073795B2 (en) * 2010-10-27 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1)
US10231817B2 (en) 2013-09-24 2019-03-19 Giner Life Sciences, Inc. System for gas treatment of a cell implant
US9872674B2 (en) * 2014-05-07 2018-01-23 Boehringer Laboratories Inc. Entrapment and containment system for use with a morcellator and method of entrapping and containing material produced during morcellation procedure
CN108260357A (en) * 2015-04-10 2018-07-06 托马斯杰弗逊大学 For reducing immunological regulation M2 monocytes treating cancer by selectivity and enhancing the method and composition of therapeutic immunity
EP3285664B1 (en) * 2015-04-23 2021-08-04 Applied Medical Resources Corporation Systems for tissue removal
WO2017066643A1 (en) 2015-10-14 2017-04-20 Bio-Path Holding, Inc. P-ethoxy nucleic acids for liposomal formulation
RU2766457C2 (en) 2017-03-09 2022-03-15 Томас Джефферсон Юнивёрсити Methods and compositions for treating cancer using antisense
JP7406213B2 (en) 2018-01-24 2023-12-27 トーマス・ジェファーソン・ユニバーシティ Biodiffusion chamber and its manufacturing method

Also Published As

Publication number Publication date
US20180256625A1 (en) 2018-09-13
JP2020510021A (en) 2020-04-02
US10357509B2 (en) 2019-07-23
WO2018165528A1 (en) 2018-09-13
BR112019018555A2 (en) 2020-04-14
MX2019010725A (en) 2020-02-10
AU2018230458A1 (en) 2019-09-05
RU2019130010A3 (en) 2021-07-05
CA3054662A1 (en) 2018-09-13
EP3592841A4 (en) 2021-01-06
US20240100078A1 (en) 2024-03-28
EP3592841B1 (en) 2024-02-14
EP3592841A1 (en) 2020-01-15
KR20190140440A (en) 2019-12-19
US11801259B2 (en) 2023-10-31
RU2766457C2 (en) 2022-03-15
US20190365794A1 (en) 2019-12-05
CN110832068A (en) 2020-02-21
US20210060055A1 (en) 2021-03-04
US20180201939A1 (en) 2018-07-19
US10772904B2 (en) 2020-09-15
JP2023081916A (en) 2023-06-13
NZ756820A (en) 2022-08-26
RU2019130010A (en) 2021-04-10
SG10202109912XA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
SG11201908054XA (en) Methods and compositions for treating cancers using antisense
SG11201907846VA (en) Therapeutic rna
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201900028VA (en) Crispr/cas9-based compositions and methods for treating cancer
SG11201806340YA (en) Zika virus vaccine
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201811457QA (en) Methods and devices for valve clip excision
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201808125RA (en) Methods for solid tumor treatment
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201900361RA (en) Methods of treating prostate cancer
SG11201906748PA (en) Microbial cells, methods of producing the same, and uses thereof
SG11201908472VA (en) Compositions and methods for activating nk cells
SG11201901411VA (en) Conditionally active polypeptides and methods of generating them